查看所有新闻bob体育竞技风暴

布鲁克(Bruker)和埃弗斯普(Evosep)宣布无偏定量的真实单细胞蛋白质组学的重大进展

2021年1月5日
  • Mann-Group的突破性新论文表明,无偏定量的真实单细胞蛋白质组学可以解决细胞生物学和单细胞病理学中的重要问题
  • 测得的单细胞蛋白和RNA水平非常不同,这意味着不同的RNA和蛋白质丰度调节机制。因此,蛋白质测量结果产生互补的定量生物学信息。
  • 结果还意味着与人口稀少的单细胞转录组相比,具有足够的蛋白质拷贝数具有足够的蛋白质拷贝数的稳定细胞核蛋白质组织具有有意义的定量单细胞蛋白质组学。

马萨诸塞州比勒里卡(Billerica),丹麦(Dens)奥登斯(Odense) - (商业资讯) -布鲁克公司(Nasdaq: BRKR) andEvoseptoday announced major progress in high-sensitivity, quantitative true single-cell proteomics, using a modifiedtimstof pro质谱仪连接到EvosepOnelow-flow chromatography system.

该新闻稿具有多媒体。在此处查看完整版本:https://www.businesswire.com/bob体育竞技风暴news/home/20210105005248/en/

图1:EVOSEP ONE LC和TIMSTOF PRO MS(照片:商务电报)

图1:EVOSEP ONE LC和TIMSTOF PRO MS(照片:商务电报)

These advances have been demonstrated by the Mann-group in a paper byA. Brunner et al.,现在可以在生物体系上获得https://www.biorxiv.org/content/10.1101/2020.12.22.423933v1。关键结果包括对真正单个细胞的第一个不靶向和无偏分析,该分析获得了从单个FACS分类和单独消化的HeLa细胞中达到1,500种蛋白质基团的鉴定深度。这种显着的敏感性是通过合并的evosep – timstofplatform using crucial innovations.

另一种未修饰的Evosep一个系统上的两种新的超低流量方法提供了100 nl/min的梯度,可在1 µL/min时梯度高约10倍,从而确认理论期望。这些使用Whisper™流技术的新型纳米流量方法的开销与其他纳米流量相同EvosepOnemethods, and offer a throughput of either 20 or 40 samples per day. They make single-cell analysis robust, as shown by the analysis of 420 single cells that were analyzed on the same column. The workflow retrieved known and unexpected proteins changing abundance upon chemically arresting the cell cycle at discrete points.

对于实现超高真实的单细胞灵敏度也是至关重要的,这是一种新的修改质谱仪,其中包括一个具有相关修改的离子光学元件的新的,更明亮的离子源。这些关于timsTOF平台与新开发的Dia-Pasef®相结合1扫描模式,其中很大一部分都peptides are sampled in an unbiased manner. The study provided further evidence of the advantages of data-independent analysis (DIA) for short LC gradients or extremely low abundance samples, such as single cells. Even for these single cells, the quantitative reproducibility was high in this novelevosep – timstof工作流程。

The authors performed an in-depth comparison to cells analyzed by single-cell RNA sequencing by two different technologies, allowing them to distinguish technical vs. fundamental biological differences between the proteomes and transcriptomes. This revealed that single cells have stable core proteomes with sufficient protein copy numbers to permit meaningful quantitation, whereas the transcriptome appears to behave more randomly, presumably because of low copy numbers of many mRNA transcripts per cell.

The principal investigator behind the Bioarchive article, Professor Matthias Mann at the Max-Planck Institute of Biochemistry, stated: “The sensitivity and robustness to truly analyze single cell proteomes is becoming a practical reality. We are now able to routinely measure cohorts of single cells, and quantitatively assess single-cell states to reveal new cell biological information. TheEvosepOneandtimstof prohave been pivotal to enable and scale these true single cell measurements, making it also a suitable platform for single-cell proteomic biomarker discovery and quantitation work.”

Bruker’s Vice President of Proteomics, Dr. Gary Kruppa, noted: “I am very excited about the new quantitative, true single cell study. This is another great example of what thetimsTOF平台可以实现,并通过DIA-PASEF方法促进了进一步的细胞生物学突破。我们预计会提供新的超高灵敏度timsTOF2021年下半年,在专用的单细胞蛋白质组学系统上,早期访问合作者的技术,我们计划在2022年进行全面商业化。”

Evosep的研究和应用负责人的合着者Nicolai Bache博士得出结论:“这种可靠的单细胞分析是迈向日常临床诊断中蛋白质组分析和数字病理学的重要一步。我们很高兴EvosepOnestands to make a significant contribution to this promising new area.”

1。‘Diapasef:并行积累 - 串行碎片结合数据无关的采集', Meier F, Brunner AD, Frank M, Ha A, Bludau I, Voytik E, Kaspar-Schoenefeld S, Lubeck M, Raether O, Bache N, Aebersold R, Collins BC, Röst HL, Mann M,Nat Methods。2020 Dec;17(12):1229-1236. doi: 10.1038/s41592-020-00998-0.

关于布鲁克公司(Nasdaq: BRKR)
布鲁克(Bruker)使科学家能够做出突破性的发现,并开发新的应用,以改善人类生活的质量。布鲁克的高性能科学仪器以及高价值分析和诊断解决方案使科学家能够在分子,细胞和微观水平上探索生活和材料。bob综合游戏与我们的客户密切合作,布鲁克正在实现创新,提高生产率和客户在生命科学,应用和制药应用,显微镜和纳米分析以及工业应用以及细胞生物学,抗旋钮成像,临床成像,临床成像,临床成像方面的生产力和成功方面的成功。bob娱乐平台现象学和蛋白质组学研究与临床微生物学。了解更多信息:www.energie2point0.com

About Evosep
Evosep的目的是通过与世界领先的科学家合作开发新技术和解决方案,使样本分离比当今的替代方案快10倍,从而提高基于蛋白质的临床诊断术,从而改善生活质量和患者护理。这需要进行快速样本处理,并且由于血液或活检形式的临床样本更粗糙,非常健壮的方案,并且还需要消耗品。阅读有关Evosep One和两个新的纳米流量方法的更多信息www.evosep.com

布鲁克媒体联系人:
佩特拉·谢弗(Petra Scheffer)
Bruker Daltonics营销传播
T: +49 (421) 2205-2843
E:[email protected]

Bruker Investor Contact:
Miroslava Minkova
投资者关系与公司发展总监
T: +1 (978) 663-3660, ext. 1479
E:[email protected]

EvosepMedia Contact:
Christian Ravnsborg,首席执行官
T: +45 26 33 20 21
E:[email protected]

资料来源:布鲁克公司

类别: Press Releases
查看所有新闻bob体育竞技风暴